share_log

Citigroup Initiates Coverage On Solid Biosciences With Buy Rating, Announces Price Target of $16

Citigroup Initiates Coverage On Solid Biosciences With Buy Rating, Announces Price Target of $16

花旗集團以買入評級啓動對Solid Biosciences的報道,宣佈目標股價爲16美元
Moomoo 24/7 ·  03/15 10:56

Citigroup analyst David Hoang initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Target of $16.

花旗集團分析師David Hoang以買入評級啓動了對Solid Biosciences(納斯達克股票代碼:SLDB)的報道,並宣佈目標股價爲16美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論